IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares gapped down prior to trading on Wednesday . The stock had previously closed at $49.15, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 190 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have commented on IPSEY. HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Barclays lowered shares of IPSEN from an “equal weight” rating to an “underweight” rating in a report on Tuesday. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

IPSEN Price Performance

The business has a 50-day simple moving average of $46.60 and a two-hundred day simple moving average of $46.76.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).